文献速递外周动脉疾病

糖尿病对周围动脉疾病患者血栓形成特征及结局的影响

The Influence of Diabetes on Thrombotic Profiles and Outcomes on Patients with Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2024-07-26

研究前瞻性纳入2020年12月至2023年7月接受下肢血运重建的周围动脉疾病患者,按糖化血红蛋白(HbA1c)水平分组,比较基线及术后1天、1个月、3个月、6个月的血栓弹力图血小板图(TEG-PM)参数。HbA1c高于6.5%者基线ADP MA、AA MA等多项指标显著升高,术后纤维蛋白原相关指标亦较高,但HbA1c仅解释参数变异的很小比例。

要点

  • HbA1c高于6.5%者基线ADP MA为52.6 vs 43.5,显著升高(P<0.01)。
  • HbA1c高于6.5%者基线AA MA为36.6 vs 29.65,显著升高(P<0.05)。
  • HbA1c仅解释血栓弹力图参数变异的很小比例,提示其他因素参与血栓形成。

核心结论

  • HbA1c升高似乎与血栓弹力图血小板图所测的促血栓形成倾向相关,尤其涉及血小板功能相关参数。
  • HbA1c仅解释这些指标变异的一小部分,强调需综合评估患者凝血特征。
  • 本研究为针对不同HbA1c水平患者个体化抗血栓策略的进一步研究奠定基础。

研究设计与样本

  • 前瞻性研究,于2020年12月至2023年7月纳入接受下肢血运重建的周围动脉疾病患者。
  • 按HbA1c水平分组,在基线、术后第1天、1个月、3个月和6个月比较血栓弹力图血小板图(TEG-PM)结果。
  • 参数包括ADP和AA的最大振幅(MA)及ADP和AA聚集百分比,采用非配对Student t检验和Mann-Whitney U检验进行组间比较。

主要发现

  • 共830份样本,HbA1c高于6.5%者基线ADP MA为52.6 vs 43.5(P<0.01),AA MA为36.6 vs 29.65(P<0.05)。
  • HbA1c高于6.5%者基线无血小板激活剂F MA为13.10 vs 10.80(P<0.01),肝素中和未抑制凝血强度MA为61.10 vs 57.70(P<0.01)。
  • 术后36小时内,HbA1c高于6.5%者枸橼酸化功能纤维蛋白原为40.95 vs 371.35(P<0.05),枸橼酸化功能纤维蛋白原MA为22.90 vs 20.40(P<0.05),该趋势在1个月随访时持续。
  • 趋势分析显示ADP MA值随HbA1c升高而进行性增加;回归分析显示HbA1c每增加1单位,ADP MA增加2.261单位,HbA1c与AA MA亦呈正相关。
  • R方值提示HbA1c仅解释这些参数变异的一小部分,提示其他因素混杂影响血栓形成。

临床怎么用

  • 作者认为,HbA1c升高似乎与促血栓形成倾向相关,尤其涉及血小板功能参数。
  • 作者指出,HbA1c仅解释这些指标变异的一小部分,强调需综合评估患者凝血特征。
  • 作者认为,本研究为针对不同HbA1c水平患者个体化抗血栓策略的进一步研究奠定基础。

局限性

  • R方值提示HbA1c仅解释这些参数变异的一小部分,提示其他因素混杂影响血栓形成。
  • 本研究为针对不同HbA1c水平患者个体化抗血栓策略的进一步研究奠定基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elevated glycated hemoglobin (HbA1c) is associated with vascular complications, including arterial thrombosis postrevascularization. However, the objective relationship between levels of HbA1c and coagulation profiles has not been established. This study aims to determine the association between specific coagulation parameters and variations in HbA1c in patients undergoing lower extremity revascularization. METHODS: Patients with peripheral artery disease undergoing revascularization were prospectively evaluated between December 2020 and July 2023. Patients were categorized based on their HbA1c levels, and their thromboelastography with platelet mapping (TEG-PM) results were compared at baseline, postoperative day 1, 1 month, 3 months and 6 months. The parameters included Maximum Amplitude (MA) with both adenosine diphosphate (ADP) and arachidonic acid (AA), as well as ADP and AA percent aggregation indicating clot strength. The study further assessed the differences in these parameters between groups with varying HbA1c levels through the use of unpaired Student's t-test for pairwise analysis and Mann-Whitney U tests. RESULTS: Among 830 samples, those with HbA1c above 6.5 demonstrated a significant increase in ADP MA (52.6 vs. 43.5, P < 0.01), AA MA (36.6 vs. 29.65, P < 0.05), clot strength without platelets activator F MA (13.10 vs. 10.80, P < 0.01), and heparin-neutralized uninhibited clot strength from thrombin activation heparinized kaolin with heparinase MA (61.10 vs. 57.70, P < 0.01) values at baseline. Postoperatively, patients with HbA1c levels greater than 6.5 had higher median functional fibrinogen citrated functional fibrinogen levels (40.95 vs. 371.35, P < 0.05) and higher formation of fibrin in response to stimulation of thrombin by tissue factor citrated functional fibrinogen MA values (22.90 vs. 20.40, P < 0.05) when measured within 36 hrs of intervention, with these trends staying consistent during the 1-month follow-up visit. The trend analysis revealed a progressive increase in ADP MA values with rising HbA1c values, indicating a unit increase in the thrombotic risk relationship. Regression analysis showed a positive relationship between HbA1c and both ADP MA (a 2.261-unit increase for each unit increase in HbA1c) and AA MA. The R-square values indicate that HbA1c only explains a small percentage of the variance in these parameters, suggesting the confounding influence of other factors contributing to thrombosis. CONCLUSIONS: Elevated HbA1c levels appear to be associated with prothrombotic tendencies in clot dynamics as measured by thromboelastography with platelet mapping, particularly in parameters related to platelet function. HbA1c explains a limited proportion of the variability in these measures, emphasizing the need for a comprehensive approach to evaluating clotting profiles in patients. This study lays the groundwork for further investigation into personalized antithrombotic strategies for patients with varying HbA1c levels.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lee I, Agrawal A, Ghandour S, et al. The Influence of Diabetes on Thrombotic Profiles and Outcomes on Patients with Peripheral Artery Disease. Ann Vasc Surg. 2024. PMID: 39067844. doi:10.1016/j.avsg.2024.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。